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Abstract
Background: Knowledge of the prevalence of morbidity secondary to stroke is important for health care professionals, health
care commissioners, third sector organizations, and stroke survivors to understand the likely progress of poststroke sequelae and
to aid in commissioning decisions, planning care, and adjusting to life after stroke.
Objective: The primary aim of the Morbidity PRevalence Estimate In StrokE (MORe PREcISE) study is to determine the
prevalence of morbidity secondary to a stroke, predictors of morbidity, and trends in quality of life and functional status using
patient-reported outcomes, cognitive and functional assessments.
Methods: A total of 500 participants will be recruited across Wales and England within 14 days following an admission to a
stroke unit for either an ischemic or hemorrhagic stroke as part of a multicenter cohort study. Participants are assessed at baseline
≤14 days poststroke and subsequently at 90 (± 14) days and 180 (± 14) days poststroke. At each time point, data will be collected
relating to the following domains: participant demographics, routine clinical, patient reported, cognitive status, emotional
well-being, and functional ability.
Results: Recruitment commenced in October 2018 with 20 sites opened as of September 2019 and was closed on October 31,
2019.
Conclusions: The primary outcome is the prevalence of morbidity at 6 months secondary to a stroke. Further analysis will
consider temporal changes in the health-related domains to describe trends among baseline, 3-, and 6-month time points.
Trial Registration: ClinicalTrials.gov NCT03605381; https://clinicaltrials.gov/ct2/show/NCT03605381
International Registered Report Identifier (IRRID): DERR1-10.2196/15851
(JMIR Res Protoc 2020;9(6):e15851) doi: 10.2196/15851
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Introduction
Stroke Morbidity
There are 1.2 million stroke survivors currently living in the
United Kingdom [1]. Although mortality as a consequence of
stroke is decreasing [1,2], over two-thirds of stroke survivors
have a form of disability on discharge from hospital [3]. During
a stroke, hypoxic injury leads to neuronal death [4,5], which
can occur in potentially any part of the brain. Thus, due to the
diverse functions of the brain, stroke can lead to significant
impairments to diverse functions and structures of the body,
resulting in a significant prevalence of morbidity secondary to
stroke [6].
The prevalence of morbidity secondary to stroke is of central
importance to health professionals to understand the prognosis
of the disease in patients under their care. Further, providing
an accurate estimation of the prevalence of morbidity secondary
to stroke will allow commissioners of care, planners, and third
sector organizations to adapt to and answer the needs of a
poststroke population. Additionally, information regarding the
likely progression of impairments secondary to stroke is
important to stroke survivors, allowing them to plan for the
future and to adjust to life after stroke.
Measures of Morbidity
Expanding data collection beyond current routinely collected
data in stroke relates to the work undertaken by the International
Consortium for Health Outcomes Measurement (ICHOM) [7]
and their minimum outcome dataset for stroke [8]. In the
ICHOM Standard Set for Stroke, a number of, what ICHOM
terms, “variables” (demographic, clinical, and treatment) and
“outcomes” (survival, disease control, and patient reported) are
included. The ICHOM Standard Set for Stroke takes important
steps to collect data outside of the process of care data in areas
such as patient-reported outcome data, which includes domains
such as toileting, walking, and assistance with feeding. However,
the ICHOM group does not advocate the specific collection of
data related to cognitive impairment or emotional problems
secondary to stroke. This study will address this by the inclusion
of measures of emotional problems and mild cognitive
impairment. Therefore, the scope of this study is to build on
routinely collected health care and poststroke data not currently
collected by the ICHOM Standard Set for Stroke for the purpose
of estimating morbidity prevalence.
Aims and Objectives
This paper describes the protocol for the Morbidity Prevalence
Estimate at 6 Months Following a Stroke (MORe PREcISE)
study (ClinicalTrials.gov NCT03605381—Registered:
30/07/19). The primary objective is to determine the prevalence
of morbidity at 6 months secondary to a stroke, predictors of
morbidity, trends in health-related quality of life (HRQoL), and
function. The definition of morbidity secondary to stroke
includes the following: aphasia, anxiety, depression, dysarthria,
dysphagia, hemianopia, hemiparesis, hemiplegia,
hemi-inattention, cognitive impairment, and functional
impairment including activities of daily living and social
interaction or roles.
Therefore, this study will collect a wide range of data related
to the most common morbidity secondary to stroke, from stroke
onset to 6 months poststroke across England and Wales. The
secondary objectives include describing trends in domains such
as HRQoL from acute onset to 6 months poststroke. It will also
explore trends in pre- and poststroke functional levels, as
assessed by the Modified Rankin Scale (mRS) [9] from the
prestroke period to 6 months poststroke. Lastly, trends in
outcomes (patient reported, functional, treatment, and process
of care) by geographical distribution, such as country, health
board/trust, local authority, and hospital (research site) coverage,
will be explored.
Methods
Study Design
This study uses a 6-month prospective cohort study of stroke
survivors and aims to recruit 500 participants between August
2018 and October 2019. Data measuring morbidity will be
collected at three distinct periods: baseline (≤14 days
poststroke), 3 months, and 6 months poststroke. This takes place
in 20 centers across England and Wales which routinely admit
acute or hyperacute stroke patients (Textbox 1). All sites were
selected after expressing an interest via the National Health
Service (NHS) research networks, and the geographic spread
was considered during site selection.
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Textbox 1. Participating research sites.
Participants:
• Aneurin Bevan University Health Board, South East Wales, United Kingdom
• Bronglais General Hospital, Aberystwyth, Wales, United Kingdom
• Glangwili General Hospital, Carmarthen, Wales, United Kingdom
• Gloucestershire Royal Hospital, Gloucester, England, United Kingdom
• Kingston Hospital, London, England, United Kingdom
• University Hospital of Wales, Cardiff, Wales, United Kingdom
• Morriston Hospital, Swansea, Wales, United Kingdom
• New Cross Hospital, Wolverhampton, England, United Kingdom
• Oxford University Hospitals, Oxford, England, United Kingdom
• Peterborough City Hospital, Peterborough, England, United Kingdom
• Prince Charles Hospital, Merthyr Tydfil, Wales, United Kingdom
• Princess of Wales Hospital, Bridgend, Wales, United Kingdom
• Somerset Partnership (SOMPAR), Somerset, England, United Kingdom
• Southmead Hospital, Bristol, England, United Kingdom
• University Hospital Lewisham, London, England, United Kingdom
• West Middlesex University Hospital, London, England, United Kingdom
• Withybush General Hospital, Haverfordwest, Wales, United Kingdom
• Wrexham Maelor Hospital, Wrexham, United Kingdom
• Yeovil District Hospital, Yeovil, England, United Kingdom
• Ysbyty Glan Clwyd, Bodelwyddan, Wales, United Kingdom
Participants and Eligibility Criteria
Participants eligible to be recruited for this study include those
aged 18 years or over with a clinical diagnosis of stroke, within
the previous 14 days; cerebral infarct (ICD I63) [10];
intracerebral hemorrhage (ICD I61) [10]; or stroke not specified
as hemorrhagic or infarction (ICD I64) [10]. Exclusion criteria
include a diagnosis of transient ischemic attack (ICD G45) [10],
subarachnoid hemorrhage (ICD I60) [10], or any condition
defined under ICD G93 (eg, anoxic brain damage) [10]. Patients
receiving palliative care or are eligible for palliative care are
also excluded from this study.
Sample Size
In order to estimate the prevalence of stroke morbidity at 6
months, assuming a 35% morbidity rate, with a 95% CI width
of ±5%, will require 350 stroke survivors. Assuming that there
is a 30% dropout [11] at the 6-month visit, the aim is to recruit
a minimum of 500 stroke survivors. This will be achieved by
aiming to approach all appropriate inpatients fulfilling the
eligibility criteria across the 20 sites. Stata Statistical software
will be used for the analyses.
Outcomes
The primary outcome is to quantify the prevalence of poststroke
morbidity, at three time points, using a range of assessments
and outcome measures, which are as follows:
• Patient-reported outcomes:
• Patient-Reported Outcomes Measurement Information
System Global Health Short Form-10 (PROMIS-10)
[12].
• Three Questions from the Riksstroke [13].
• Two Questions from the ICHOM Standard Stroke Set
for Stroke [8].
• Cognitive status:
• Short-Form Montreal Cognitive Assessment
(SF-MoCA) [14] (domains, clock drawing, abstraction,
five-word recall).
• Telephone Montreal Cognitive Assessment Short
(T-MoCA-Short) [15] (domains, verbal fluency,
orientation, five-word recall).
• Emotional well-being:
• Patient Health Questionnaire-4 (PHQ-4) [16].
• PHQ-9 [17].
• Generalized Anxiety Disorder-7 (GAD-7) [18].
• Functional ability:
• Modified Rankin Scale [9].
• Rankin Focused Assessment (RFA) [19].
• Treatment:
• Recurring stroke (cerebral infarct [ICD I63]),
intracerebral hemorrhage [ICD I61], and stroke not
specified as hemorrhage or infarction [ICD I64] [10].
• Process:
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• Length of stay following primary admission for stroke.
• Readmission to hospital within 30 days of discharge.
Data Collection
Following enrolment into the study, data collection is divided
into three distinct periods: Period A (within 14 days from the
onset of stroke), Period B (90 days poststroke ± 14 days), and
Period C (180 days poststroke ± 14 days) as per the participant
flow diagram (Figure 1). A standardized SPIRIT (Standard
Protocol Items: Recommendations for Interventional Trials)
[20] schedule of assessments is presented in Figure 2.
Figure 1. Participant flow diagram. Electronic Case Report Form/Case Report Form (eCRF/CRF).
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Figure 2. SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) checklist. SF MoCA: Short-Form Montreal Cognitive
Assessment; T-MoCA-Short: Telephone Montreal Cognitive Assessment Short; PROMIS-10: Patient-Reported Outcomes Measurement Information
System Global Health Short Form-10; ICHOM: International Consortium Health Outcomes Measurement; PHQ-4: Patient Health Questionnaire-4;
GAD-7: Generalized Anxiety Disorder-7; PHQ-9: Patient Health Questionnaire-9; mRS: Modified Rankin Scale; RFA: Rankin Focused Assessment.
Period A—Within 14 Days of Stroke Onset
Period A begins following consent or following consultee
declaration with data collection attempted as soon as possible
during the participant’s admission. Baseline data collection will
occur at 14 days or less poststroke and before discharge from
hospital. All data will be collected using Case Report Form A
(CRF A). There is a further window of 24 hours available for
data collection if necessary. Baseline data will not be recorded
outside these time points. Additionally, provided consent was
received before discharge, data collection from the participant
may occur after discharge to the community if no opportunity
arose prior to discharge.
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The baseline data collected comprise participant demographic
and routine clinical data including their prestroke lifestyle data,
cognitive assessment, Patient Reported Outcome Measure
(PROM), and anxiety and depression screen. Demographic data
are collected via medical notes or a care team and then
confirmed by the participant or participant’s family or friends.
An equivalent process will be undertaken to gather prestroke
lifestyle data.
During baseline data collection, a cognitive screen will be
administrated in the form of a SF-MoCA [14]. Alongside this
assessment, the participants are required to self-complete a
PROM using the PROMIS-10 [12], Riksstroke questions [13],
and ICHOM questions [8]. Participants will also self-complete
a PHQ-4 [16]. If the PHQ-4 is positive, as indicated by a score
≥3 for the sum of questions 1 and 2 or 3 and 4, for anxiety or
depression, the patient will then self-complete the PHQ-9 [17]
and GAD-7 [18]. If the participants are unable to self-complete,
the study allows for assessments or outcomes to be administered
verbally.
To gain a representation of any prestroke disability in
participants, a prestroke mRS [9] will be completed. This must
be carried out by a suitably trained health care professional.
RFA [19] will be carried out by a suitably trained health care
professional for an estimate of the level of poststroke disability.
60 Days Poststroke (± 7 Days)
Between Periods A and B at 60 days poststroke, it should be
established whether the participant remains as an inpatient or
is discharged. It should be ascertained whether the participant
has deceased, had another stroke, or is eligible for or already
receiving palliative care. In the case of further stroke or
palliative status, a serious adverse event (SAE) form should be
completed and the participant should be withdrawn from the
study. In the event of an unscheduled admission, an adverse
event or SAE form should be completed and the principal
investigator (PI) should be informed. The PI makes the decision
regarding whether the participant should continue to participate
or be withdrawn from the study. Participants themselves or their
consultees have the right to withdraw from the study at any
time, without providing a reason.
The research site team will ensure the accuracy of participant’s
address and contact details on file, which may be confirmed
using primary and secondary care–linked health records to
ensure accuracy. To ensure participant retention, following these
checks, a study involvement reminder letter should be sent to
the participant’s home address, provided they have been
discharged.
Period B—90 Days Poststroke (± 14 Days)
At this point, within the study, it is expected that a large
proportion of participants will reside in the community.
Therefore, participants are to receive study follow-up via either
telephone or face-to-face appointment [21]. Telephone
appointments should be scheduled with the participant to
complete the patient-reported aspect of CRF B via the telephone.
Follow-up appointments should be arranged to fall within the
90 days (± 14 days) poststoke window of opportunity, and a
maximum of three attempts should be made to contact the
participant. In circumstances where three unsuccessful attempts
have been made to contact the participant or if the window of
opportunity has elapsed, then the participant is to be considered
lost to follow-up.
Face-to-face appointments can be used by research sites as a
first preference. Participants with either or both communication
difficulties and prestroke or poststroke cognitive impairment
should be offered the option of either face-to-face or telephone
appointments. The face-to-face follow-up appointments should
be conducted in accordance with procedures outlined in Period
A (≤14 days poststroke) data collection.
If participants are yet to be discharged from the hospital by 90
days (± 14 days) poststroke or have been rehospitalized, for
reasons other than further stroke, then participants can also be
followed up with CRF B but in line with procedures outlined
in Period A (≤14 days poststroke) data collection.
150 Days Poststroke (± 7 Days)
This occurs between Periods B and C at 150 days poststroke (±
7 days). The procedure is identical to that outlined in the 60-day
poststroke section of this protocol paper, which should be
repeated at the 150-day poststroke (± 7 days) time point.
Period C—180 Days Poststroke (± 14 Days)
Data collection at this point is identical to Period B (90 days
poststroke). The procedure for this period should be repeated
exactly as outlined in the Period B section of this protocol paper
using CRF C at the 180-day poststroke (± 14 days) window of
opportunity.
Long-Term Data Collection
Further funding may be sought to obtain repeat data
measurement at future time points, in keeping with the
recommendation of the ICHOM Standard Set for Stroke.
Currently, there are no defined plans for these types of data
collection, but all data will be collected using assessments and
outcome measures as outlined in the protocol presented in Figure
2.
Completion of Assessments, Screens, and
Patient-Reported Outcomes
Response options for these data are either complete or
incomplete and whether the participant is able or unable to
self-complete the relevant PROMs, cognitive screen, and anxiety
and depression screen. If the participant is unable to
self-complete, then the reason for non–self-completion is to be
recorded. Where participants cannot self-complete but are able
to give verbal responses, then baseline data collection of
PROMs, assessments, and screens are to be administered
verbally to ensure that all questions are completed. If the
participant is unable to give responses when verbal
administration is attempted, the reason for this noncompletion
should be recorded on the CRF. Reasons for both
non–self-completion and noncompletion of verbal administration
should be identified as either potentially cognitive or physical
impairment.
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Cognitive Causes of Noncompletion
Cognitive causes of noncompletion should be recorded on the
CRF, and no further attempt at patient-reported data collection
should be made at this time. Cognitive causes of noncompletion
include, but are not limited to, the following:
confusion,drowsiness, history of dementia, aphasia—expressive
or receptive, and anosognosia.
Physical or Visual Causes of Noncompletion
If the suspected reason for non–self-completion is physical or
visual impairment, then the participant is to be provided
assistance to complete the PROMs, cognitive screen, and anxiety
and depression screen. The administrator should read the
question and note down the response. However, there should
be no deviation from the wording of the questions or response
options. Potential physical or visual deficits that could be
expected are as follows: hemiparesis, hemiplegia,
hemi-inattention, and hemianopia.
During Periods B and C, if the participant is unable to complete
the PROM, cognitive screen, or anxiety and depression
screening questions via telephone, a decision about whether a
suitable alternative follow-up method is appropriate should be
made. This is to be based on clinical judgment, provided the
participant still wishes to continue in the study.
During collection of data, the use of secondary sources to aid
data collection is permitted for the following; demographic,
clinical, lifestyle, poststroke sequelae and functional
assessments. The participant’s family, friends, care team, or
medical notes are permissible sources of consultation. However,
secondary sources are not permitted to aid the completion of
the patient-reported data such as cognitive screen, PROM, or
anxiety and depression screen.
Data Analysis
The objective of this study is to estimate the prevalence of
morbidity at 6 months with a 95% CI width of ±5%.
The study will be deemed to have ended following the collection
of data for Period C from the last participant registered in the
study. All participants recruited in the study will be included
in the analysis population. All clinical characteristics will be
presented in a descriptive narrative.
Morbidity Prediction
Baseline clinical and patient demographic variables will be used
to predict the mediating effects of a patient exhibiting poststroke
morbidity.
Continuous outcomes are analyzed using a mixed-effects linear
model, and binary outcomes are analyzed using logistic
regression. All estimates will be presented with 95% CI. Sites
will be fitted by a random intercept model. For outcomes that
analyze at a single time point, we will fit a single random
intercept of patients nested within the site using a random
intercept model. Moreover, we will be fitting a three-tier
multilevel model, including two random intercepts. Multiple
patient time points will be fitted within a patient, and the patient
will be fitted within a site. Statistical analysis will be performed
using Stata Statistical software (StataCorp LLC).
Psychometric Analysis
The patient-reported outcomes will be assessed for the following
psychometric properties: validity (content validity and
convergent validity) and reliability (internal consistency).
Missing Outcome Data
Due to the nature of our data collection methods, and evidence
from previous studies of this nature, we anticipate negligible
missing instrument levels, and in this case, a complete case
analysis will be carried out. If the level of missing outcome data
is not considered negligible (>5%), missing data will be explored
for patterns of missingness and may be imputed using
appropriate methods. Imputation methods will depend on the
proportion of missingness and reason for the missing data.
Ethical and Regulatory Considerations
Ethical approval has been granted by an NHS Research Ethics
Committee (REC; 18/WA/0299) before recruitment for the
study began. The NHS REC has reviewed the study protocol
and all relevant trial materials. Where necessary, the REC will
review any amendments or alterations to the study design or
conduct.
The protocol was developed using the SPIRIT guidelines [20]
and a completed SPIRIT checklist is included Multimedia
Appendix 1.
Amendments
Amendments will be internally reviewed at the coordinating
center, and no study amendments will proceed without prior
approval of the study sponsor. Amendments that require review
by NHS REC will not be implemented until full REC approval
has been obtained for the amendment under review and the local
participating NHS organization approvals are in place to
implement the amendment at the research site. The coordinating
center will work with the participating research site to ensure
that the necessary arrangements are in place to implement the
amendment. The full amendment history of the study protocol
will be tracked in the appropriate section of the protocol.
Data Management
Data will be collected by appropriate health care staff appointed
by the PI, and training will be provided by the study team for
the delivery and use of assessments required to complete the
data collection. A secure online data input and management
system is used for all study data. Regular data inspection and
quality control will be performed throughout the lifetime of the
study. Research sites will retain identifiable study data securely
for a minimum of 5 years. Anonymous study data at the study
office level will be held for 10 years in line with the sponsor’s
requirements. The data custodians will work together to establish
a suitable trial data repository for the anonymized study dataset
following the conclusion of primary and secondary data
analyses.
Data Monitoring and Oversight Committee
The Data Monitoring and Oversight Committee (DMC) will
convene to oversee the study by providing independent scrutiny
of the progress and conduct of the study. The committee consists
of a funder’s representative, sponsor’s representative, patient
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representative/s, and an independent member. The patient’s
representative/s will be stroke survivor/s or relative/s or carer/s
of a stroke survivor with an interest in stroke care or research.
The independent member will be an academic (clinical academic
or academic involved in the design and conduct of clinical
research) or a suitably qualified health care professional with
experience, knowledge, and understanding of the design and
conduct of clinical research. Moreover, the independent member
will have no institutional affiliation with the chief investigator,
coinvestigators, research team at the coordinating center,
sponsor, or funder nor will the independent member be involved
in the design or conduct of the study. All independent members
of the DMC listed previously will have full voting rights.
Study Sponsor and Funder
The sponsor, Aneurin Bevan University Health Board, will
provide institutional level support for this study. They will
ensure safe and proper conduct of the study in line with the
International Conference on Harmonization Guideline for Good
Clinical Practice and the Declaration of Helsinki [22] and
reserve the right to audit all study documents and standard
operating procedures at the coordinating center and research
sites. The sponsor and the funder (Stroke Implementation Group
of the Welsh Government) are entirely independent of the study
and have no influence or involvement in the trial design or
decision to publish results.
Protocol Compliance
Compliance with the protocol and study procedures must be
monitored at the research site by the PI, whereas compliance
of all study sites will be monitored by the coordinating center,
study sponsor, and DMC. Deviations will be monitored by the
supplied deviation log, and all deviations must be reported to
the study coordinating center within 24 hours of the discovery
of the deviation.
All deviations should be reported to the PI at the research site,
and all deviation logs are to be ratified by the PI at the research
site before they are reported to the coordinating center. The
coordinating center will classify the nature of the deviation and
will either request the completion of the corrective and
preventive action (CAPA) form or, depending on the severity
of the deviation, may escalate the deviation to the study sponsor,
DMC, local NHS organization research and development
department, and national research authority. Adherence to the
CAPA outlined in the CAPA form is ultimately the
responsibility of the PI. Where deviations from the protocol are
found to reoccur, immediate action will be required and such
instances could potentially be classified as a serious breach of
the protocol or Good Clinical Practice (GCP). Moreover, where
deviations are previously the subject of a CAPA, they will be
reviewed by the coordinating center, study sponsor, and
potentially the DMC. Continued deviations, especially those
deviations previously resulting in a CAPA, may be escalated
to the local NHS organization’s Research and Development
department, which is the national research authority and may
result in the suspension of recruitment at the research site.
Serious breaches of GCP or protocol should also be self-referred
by the PI at the research site to the appropriate research
governance authority, in line with the applicable local and
national guidelines.
Access to the Final Study Dataset
Access to the final deidentified study dataset will be restricted
to the chief investigator, coinvestigators, data manager, and
study sponsor. Granting access to the final deidentified study
dataset to third parties must be unanimously agreed by the chief
investigator and study sponsor. Thus, the chief investigator and
the study sponsor will jointly hold the role of data custodians
for the study. All requests to access the final study dataset are
to be made formally in writing to all those acting as data
custodians, whereby all intended analyses are outlined clearly.
Acting as a PI this does not grant the individual named as PI at
the research site the right to utilize any data arising from the
trial. Those PIs wishing to utilize any data resulting from the
trial must formally request, in writing, permission to analyze
any part of the data arising from the study. Access to the final
data will only be granted with the unanimous agreement of the
data custodians. Those given access to the final study dataset
are only permitted to undertake analyses as outlined in the
formal request. A further formal request must be made to the
data custodians to adapt, change, or run new analyses not
outlined in previous formal requests. The data custodians will
work together to establish a suitable trial data repository for the
anonymized study dataset following the conclusion of all
primary and secondary data analyses
Consent
Informed Consent
All potentially eligible participants will have the capacity to
offer valid and informed consent assessed. Potentially eligible
participants who do not have the capacity to offer informed
consent can also take part in the study through the use of a
consultee, thereby ensuring that the study cohort is
representative of the poststroke population.
In line with the Mental Capacity Act (2005) England and Wales
[23], the potentially eligible participant’s capacity to consent
will be presumed unless it is established otherwise. Informed
consent will be sought from those potentially eligible
participants, where a lack of capacity to consent could not be
established as outlined under the Mental Capacity Act (2005)
[23].
All potentially eligible participants with the capacity to consent
are to be presented with the most current version of the
participant information sheet and given a minimum of 24 hours
to consider their participation in the study and ask questions or
request clarifications. Following this period, written informed
consent will be sought from all potential participants with the
capacity to consent from the PI or a registered health care
professional delegated by the PI.
Aphasia or Communication Difficulties
Participants who present with or have a known diagnosis of
aphasia or communication difficulties and have the capacity to
provide informed consent should be approached using the latest
version of the aphasia or communication difficulty–specific
participant information sheet.
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Limb Weakness or Paralysis
If a patient is unable to sign the consent form due to limb
weakness or paralysis but has the capacity to provide informed
consent, then oral consent will be taken in the presence of a
witness, who must not be involved in the study in any capacity.
The witness must sign the designated witness consent area on
the consent form on behalf of the participant.
Consultee
A consultee must be sought when a potential participant who,
under the provisions of the Mental Capacity Act (2005) [23],
cannot provide informed consent. The consultee is to be
provided with the most current version of the consultee
information sheet and should be given a minimum of 24 hours
to consider the wishes of the potential participant. Following
this period of reflection, a written declaration must be obtained
from the consultee if he/she believes the potential participant
would have no objections to taking part in the study. Those
participants who do not regain the capacity to consent are to
remain under the consultee declaration for the duration of the
study. The consultee has the right to advise the withdrawal of
the participant from the study at any time without giving a
reason. Moreover, participants have the right to withdraw their
participation at any time if they indicate signs of unwillingness
to participate.
Regaining Capacity to Offer Informed Consent
The loss of capacity to offer informed consent should not be
considered as a fixed state, and the assessment of capacity to
offer informed consent should not be considered as a final
decision to be applied across the whole of the study period.
Consultees should be informed that they are to make the study
team aware if they believe the participant has regained the
capacity to offer informed consent. Participants suspected of
regaining capacity to offer informed consent are to be given the
most recent version of the regained capacity participant
information sheet and 24 hours to consider their continued
participation in the study and to ask any questions or
clarifications. Subsequently, the participant should be asked to
provide informed consent. Alternatively, if a participant wishes
to decline continued participation, he/she should be withdrawn
from the study. Anonymized data collected prior to withdrawal
will be used in the study analysis.
Loss of Capacity to Offer Informed Consent
Where it is determined that a participant has lost his/her capacity
to offer informed consent, help should be sought from the
appointed consultee. Nominated consultees will be made aware
of their status as a nominated consultee when the participant
initially consents to the study. Therefore, the nominated
consultee is to be provided with the appropriate information
sheet and given 24 hours to consider if he/she believes that the
participant has no objections to continuing to participate in the
study. Following the period of reflection, where the consultee
believes that the participant would have no objections to
continuing in the study, he/she will complete a consultee
deceleration form. If the consultee believes that the participant
would not want to continue to participate in the study, then the
participant should be withdrawn. All anonymized data collection
prior to withdrawal will be utilized in the study analysis.
Further Contact
All consent and consultee declaration forms include an optional
section, which asks participants or consultees to consent to or
declare to being contacted at future time points poststroke to
seek further consent or consultee declaration to participate in
answering longer-term follow-up questions for the study.
Confidentiality
Data will be collected and stored in line with the General Data
Protection Regulations [24]. Following the receipt of informed
consent, each participant will be anonymized and assigned a
unique 6-digit Participant Research Number (PRN). Data
collected for each participant will be stored alongside their PRN.
These tables will not contain any identifiable information from
participants. A separate database linking the PRN to the
participant’s NHS number will be stored at the research site.
This database will be encrypted and restricted to named
researchers only under the direct supervision of the PI.
Information shared by the research team to the lead researchers
outside of the individual research site will be completely
anonymized, and lead researchers will only have access to data
stored against the PRN. Following the conclusion of the study,
the anonymized data will be archived for a period of 10 years
in line with the sponsor’s requirements.
Results
Recruitment opened in October 2018, with 536 participants
recruited and 20 sites opened in England and Wales as of
September 2019. Patient recruitment was closed on October
2019, with follow-up occurring until April 2020. Data analysis
is scheduled to start after all data have been collected, with an
aim to publish a peer-reviewed article in late 2020.
Discussion
This study aims to assess morbidity poststroke using
patient-relevant outcome measures. Assessment of morbidity
in stroke survivors will indicate the prevalence and type of
morbidity to allow for the concentration of support needed for
stroke survivors in these areas.
The research team will plan a longer term follow-up of
participants of the MORe PREcISE study to explore further
changes in morbidity, outcomes, and quality of life.
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